These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20526101)

  • 1. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
    Serrano C; Markman B; Tabernero J
    Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
    Prenen H; Tejpar S; Van Cutsem E
    Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic colorectal cancer.
    Saletti P; Cavalli F
    Cancer Treat Rev; 2006 Nov; 32(7):557-71. PubMed ID: 16935430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived.
    O'Neil BH; Goldberg RM
    Expert Opin Investig Drugs; 2003 Dec; 12(12):1939-49. PubMed ID: 14640938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
    Van Cutsem E
    Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular markers in the treatment of metastatic colorectal cancer.
    Wilson PM; Labonte MJ; Lenz HJ
    Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
    Engstrom PF;
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in the treatment of metastatic colorectal cancer.
    Leong S; Messersmith WA; Tan AC; Eckhardt SG
    Cancer J; 2010; 16(3):273-82. PubMed ID: 20526106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
    Marshall JL
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating new data on colorectal cancer into nursing practice.
    Viale PH
    Clin J Oncol Nurs; 2010 Feb; 14(1):92-100. PubMed ID: 20118032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the management of metastatic colorectal cancer.
    Comella P; Casaretti R; Avallone A; Franco L
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):15-26. PubMed ID: 19837601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel targets for anticancer treatment development in colorectal cancer.
    Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
    Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of targeted therapy on the treatment of colorectal cancer.
    Marshall JL; Hwang J
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 6):19-24. PubMed ID: 16502666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.
    Price TJ; Tebbutt NC; Karapetis CS; Segelov E; Pavlakis N; Cunningham D; Sobrero AF; Haller DG; Shapiro JD
    Clin Colorectal Cancer; 2010 Jan; 9(1):8-14. PubMed ID: 20100683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.